Fresenius Group Overview

January 19, 2011

Fresenius Medical Care awarded first contract for comprehensive dialysis care and performance-oriented reimbursement in Spain

Fresenius Medical Care AG & Co. KGaA ("the Company" or "Fresenius Medical Care"; Frankfurt Stock Exchange: FME / New York Stock Exchange: FMS), the world's largest provider of dialysis products and services, today announced a cooperation agreement with the public health authorities in the Murcia region of Spain for the country's first comprehensive dialysis care and performance-oriented reimbursement model. Under this agreement, Fresenius Medical Care will provide dialysis therapy to approximately 200 renal patients in the region. The contract will be effective from mid-2011.

Similar to the system introduced in Portugal three years ago, reimbursement will be converted to an all-inclusive "bundled" rate that is tied to Fresenius Medical Care's quality performance. The Company currently provides dialysis treatment and related products to patients in the region of Murcia on a "fee-for-service" basis.

Dr. Emanuele Gatti, chief executive officer for Europe, Latin America, Middle East and Africa as well as global chief strategist of Fresenius Medical Care said: "As a vertically integrated dialysis company with longstanding experience, we are the right partner for successful, long-term cooperation with public health authorities such as those in Murcia and other payors. Together we can make a lasting improvement in the quality of dialysis patients' lives while helping ease the current strain on budgets by making health care spending more efficient."

Fresenius Medical Care is the largest private dialysis provider in Spain, with annual revenues of approximately $270 million from patient care and dialysis products. Currently, the Company provides dialysis treatment to more than 5,500 patients in 64 dialysis clinics. According to the Spanish Society of Nephrology, about 1,100 patients per 1 million individuals need renal replacement therapy in Spain in the form of dialysis or transplantation to survive. The Murcia region, located on the Mediterranean coast in the southeast, is one of the Company's key markets on the Iberian Peninsula. The region is one of the country's 17 autonomous communities. In Spain, regional governments are responsible for the administration of health, social and other services.

Fresenius Medical Care is the world's largest integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 1.89 million individuals worldwide. Through its network of 2,716 dialysis clinics in North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius Medical Care provides dialysis treatment to 210,191 patients around the globe. Fresenius Medical Care also is the world's leading provider of dialysis products such as hemodialysis machines, dialyzers and related disposable products. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME, FME3) and the New York Stock Exchange (FMS, FMS/P).

For more information about Fresenius Medical Care, visit the company's website at www.fmc-ag.com.

This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.